Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05061992 · ClinicalTrials.gov registry record · Phase 2
A Trial to Improve Quality of Life in People With Cirrhosis
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT05061992 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 56 participants.
The verdict
NCT05061992, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This trial is being completed to evaluate whether a crystallized form of lactulose (Kristalose) will improve quality of life, sleep and cognitive function in patients with cirrhosis that have not been diagnosed with Hepatic Encephalopathy (HE), but report reduced quality of life.
Interventions
- DRUG Lactulose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-11-10 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05061992
The ClinicalTrials.gov registry entry for NCT05061992 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lactulose is the first listed.
NCT05061992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05061992 about?
NCT05061992 is a clinical study titled "A Trial to Improve Quality of Life in People With Cirrhosis". This trial is being completed to evaluate whether a crystallized form of lactulose (Kristalose) will improve quality of life, sleep and cognitive function in patients with cirrhosis that have not been diagnosed with Hepatic Encephalopathy (HE), but report reduced quality of life.
What is the current status of trial NCT05061992?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2021-11-10. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT05061992?
The interventions under investigation include: Lactulose (DRUG).
Who is sponsoring clinical trial NCT05061992?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.